# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

> **NCT03257046** · PHASE1,PHASE2 · COMPLETED · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** ITI-214
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03257046
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-09-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257046, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03257046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*